Dr. J. Carl Barrett is Vice President of Translational Medicine at AstraZeneca Oncology where he is responsible for development and execution of biomarker strategies and translational research efforts to support drug development across the entire oncology portfolio. The TM team consists of experts in genomics, proteomics, computational biology, informatics, computational pathology and AI. From 2005-2011, he was Global Head of Oncology Biomarkers and Imaging in Novartis Oncology Translational Medicine.
Dr. Barrett’s research interests at NIH focused on discovery of critical genetic and epigenetic changes in the cancer cell, in particular the discovery of genes involved in breast cancer (BRCA1) in cellular senescence (SIRTs, TERT) and cancer metastasis (KAI1) and the role of the biosystem in cancer. Since joining Pharma, he has contributed to the development of multiple drugs and diagnostics. He is also actively involved in external cancer research efforts (FNIH, FOCR, BloodPac, ARPA-H)